Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by juniper88on Nov 22, 2019 11:52am

155 Views

Post# 30382651

RE:RE:Weekly Sales Update

I believe another thing worth pointing out is that even though sales have not been as good as we had all hoped for, as the PPS has slide TH is now trading less than 4x current sales.

SPCEO1 wrote: It is worth pointing out that the comparisons are Bloomberg numbers to Bloomberg numbers. Since Bloomberg was way too high in Q3 versus the actual reported numbers, if the Bloomberg numbers are more accurate this quarter (unlikely) then the percentage increase from Q3 is much higher than 7%. Now, the Bloomberg estimates could be overstating reality again as they did in Q3 or they could be too low, as they were in Q1 and Q2. So, the range of possible outcomes is very wide. But the trend in Torgarzo sales does appear to be an upwards one.

SPCEO1 wrote: Trogarzo sales fell from last week’s record weekly total but still produced a number that has the quarterly sales growth looking to be around 7% with two weeks of data yet to be reported. Sales through the first two months of the quarter were up about 1% but if Trogarzo sales did only reasonably well in November, the full quarter results would look pretty good (because August Trogarzo sales were so low, it is an easy comparison) and so far that is what is happening. Not only are Trogarzo sales in November reasonable, they are much better than August. Now, we know that the Thanksgiving holiday will limit sales in the last week of the month so those numbers, which we will get in a couple of weeks, will pull the November Trogarzo sales number down some, but if the Bloomberg numbers are not way off the mark (and they have usually been way off the mark on a quarterly basis) then Trogarzo growth should be pretty good in Q4. Most of the time, Bloomberg has underestimated actual sales, so the numbers might be even better than what is indicated by Bloomberg for Q4 so far.

Egrifta sales had the best week since September, so maybe it is beginning to pull out of its mini-sales slump that is saw in October. While Trogarzo looks to be about 7% ahead of Q3, Egrifta sales are about 7% behind Q3 levels, again all according to Bloomberg which we know is less than perfectly reliable.